Vericel Posts 2Q18 MACI Revenue Growth

By Julie A. Vetalice

For 2Q18, Vericel posted MACI orthobiologic revenue of US $14.1MM, +9.3% vs. 2Q17, with 1H18 revenue of $26.2MM, +46.3% vs. 1H17.

Member-Only Content

SUBSCRIBE Login

Product Labels: Orthobiologic Soft Tissue Repair

Tags: Revenue Report